Physician profile
Mark A Steele
NPI 1053385542
$4,315.74
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $690 · 2021: $236 · 2022: $1,093 · 2023: $836 · 2024: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.53 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $672.43 | 2019-2020 | |
| Astellas Pharma US INC | $509.41 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $383.44 | 2019-2023 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Sumitomo Pharma America, INC. | $287.74 | 2023-2024 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $283.91 | 2019-2024 | |
| Aspira Women'S Health INC | $261.91 | 2020-2023 | Ova1 |
| Biohaven Pharmaceuticals, INC. | $191.10 | 2020-2021 | |
| Amgen INC. | $145.74 | 2019-2021 | |
| Myovant Sciences INC. | $137.91 | 2022 | |
| Exeltis, USA INC. | $121.63 | 2022-2024 | Slynd |
| Daiichi Sankyo INC. | $118.45 | 2019-2023 | Injectafer |
| Biohaven Pharmaceutical Holding Company Ltd. | $118.00 | 2022 | |
| Mayne Pharma Commercial LLC | $117.37 | 2022-2024 | |
| Pfizer INC. | $101.41 | 2023-2024 | |
| Sage Therapeutics, LLC | $99.18 | 2023-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $95.52 | 2019-2023 | Gardasil 9 |
| Therapeuticsmd, INC. | $86.87 | 2019-2020 | |
| Channel Medsystems, INC. | $82.82 | 2023 | |
| Avion Pharmaceuticals | $74.51 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.07 | 2019-2022 | |
| Allergan, INC. | $53.14 | 2019-2020 | |
| Novo Nordisk INC | $45.96 | 2024 | Wegovy |
| Coopersurgical, INC. | $34.49 | 2019-2022 | |
| Becton, Dickinson and Company | $34.41 | 2019-2021 | |
| Organon LLC | $28.78 | 2022-2023 | |
| Ascend Therapeutics US, LLC | $24.07 | 2024 | |
| Alexion Pharmaceuticals, INC. | $20.42 | 2022 | |
| Radius Health, INC. | $17.31 | 2019 | |
| Covidien Lp | $16.67 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.58 | 2020 | |
| Hologic Sales and Service, LLC | $13.16 | 2024 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Scynexis, INC. | $12.72 | 2022 | |
| Evofem Biosciences, INC. | $12.66 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.87 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.27 | 2020 | |
| Vivus LLC | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.